News

The portfolio includes more than 30 generic injectable products. These products will require to be technology transferred and could be launched within the next one to two years.

The intended clinical trial will be a proof-of-concept study combining Novo Nordisk’s semaglutide (GLP-1 analogue) and Gilead’s cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of

Balversa is now indicated in the US for the treatment of adult patients having locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration

The investment in AskBio includes an amount of $225m committed by global alternative asset firm TPG Capital and life sciences investment firm Vida Ventures in exchange of a

Wockhardt’s Decitabine Injection is a generic version of Dacogen, marketed in USA and other countries by Otsuka. Decitabine is used to treat Myelodysplastic syndromes (MDS), a group of

The trial, called DIAMOND, is the first prospective phase 3 trial which is assessing the rapid initiation of a single-tablet regimen (STR) SYMTUZA for the treatment of human

The study will be conducted at the Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta. “Given the exciting data Emory University researchers presented at the

The latest approval for Lynparza in Europe is for its use as a monotherapy for adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth factor

Referred to as TIMES (Trials of IMeglimin for Efficacy and Safety), the Imeglimin Phase 3 program in Japan includes three pivotal trials to evaluate Imeglimin’s efficacy and safety